The Host Defense Peptide Cathelicidin Is Required for NK Cell-Mediated Suppression of Tumor Growth

Tumor surveillance requires the interaction of multiple molecules and cells that participate in innate and the adaptive immunity. Cathelicidin was initially identified as an antimicrobial peptide, although it is now clear that it fulfills a variety of immune functions beyond microbial killing. Recent data have suggested contrasting roles for cathelicidin in tumor development. Because its role in tumor surveillance is not well understood, we investigated the requirement of cathelicidin in controlling transplantable tumors in mice. Cathelicidin was observed to be abundant in tumor-infiltrating NK1.1 + cells in mice. The importance of this finding was demonstrated by the fact that cathelicidin knockout mice ( Camp 2 / 2 ) permitted faster tumor growth than wild type controls in two different xenograft tumor mouse models (B16.F10 and RMA-S). Functional in vitro analyses found that NK cells derived from Camp 2 / 2 versus wild type mice showed impaired cytotoxic activity toward tumor targets. These findings could not be solely attributed to an observed perforin deficiency in freshly isolated Camp 2 / 2 NK cells, because this deficiency could be partially restored by IL-2 treatment, whereas cytotoxic activity was still defective in IL-2-activated Camp 2 / 2 NK cells. Thus, we demonstrate a previously unrecognized role of cathelicidin in NK cell antitumor function. The Journal of Immunology , 2010, 184: 000–000.

[1]  S. Mohr,et al.  Vitamin D for cancer prevention: global perspective. , 2009, Annals of epidemiology.

[2]  D. Schadendorf,et al.  NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. , 2009, The Journal of clinical investigation.

[3]  F. Marini,et al.  The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells , 2009, Proceedings of the National Academy of Sciences.

[4]  S. Krishnamurthy,et al.  Cutting Edge: Down-Regulation of MHC Class I-Related Chain A on Tumor Cells by IFN-γ-Induced MicroRNA1 , 2009, The Journal of Immunology.

[5]  C. Chuang,et al.  Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. , 2008, Human gene therapy.

[6]  C. Dumitru,et al.  NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model , 2009, Cancer Immunology, Immunotherapy.

[7]  F. Granath,et al.  Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer , 2009, Breast Cancer Research.

[8]  Svetlana Shulga Morskaya,et al.  5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma , 2008, Nature Medicine.

[9]  S. Coffelt,et al.  Tumors sound the alarmin(s). , 2008, Cancer research.

[10]  A. Di Nardo,et al.  Mast Cell Cathelicidin Antimicrobial Peptide Prevents Invasive Group A Streptococcus Infection of the Skin1 , 2008, The Journal of Immunology.

[11]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[12]  Ruth S. Waterman,et al.  Ovarian cancers overexpress the antimicrobial protein hCAP‐18 and its derivative LL‐37 increases ovarian cancer cell proliferation and invasion , 2007, International journal of cancer.

[13]  R. Gallo,et al.  Innate immunity and antimicrobial defense systems in psoriasis. , 2007, Clinics in dermatology.

[14]  Sarah R Dennison,et al.  The interactions of aurein 1.2 with cancer cell membranes. , 2007, Biophysical chemistry.

[15]  Jack D Bui,et al.  Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? , 2007, Current opinion in immunology.

[16]  Y. Helfrich,et al.  Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. , 2007, The Journal of clinical investigation.

[17]  A. Di Nardo,et al.  Cathelicidin Antimicrobial Peptides Block Dendritic Cell TLR4 Activation and Allergic Contact Sensitization1 , 2007, The Journal of Immunology.

[18]  M. Smyth,et al.  Innate tumor immune surveillance. , 2007, Advances in experimental medicine and biology.

[19]  A. Rao,et al.  Chromosome transfer activates and delineates a locus control region for perforin. , 2007, Immunity.

[20]  A. Goldrath,et al.  Transcriptional regulator Id2 mediates CD8+ T cell immunity , 2006, Nature Immunology.

[21]  R. Gallo,et al.  Control of the innate epithelial antimicrobial response is cell‐type specific and dependent on relevant microenvironmental stimuli , 2006, Immunology.

[22]  T. Hökfelt,et al.  The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection , 2006, Nature Medicine.

[23]  M. Flaig,et al.  Cathelicidin deficiency predisposes to eczema herpeticum. , 2006, The Journal of allergy and clinical immunology.

[24]  T. Ng,et al.  Sesquin, a potent defensin-like antimicrobial peptide from ground beans with inhibitory activities toward tumor cells and HIV-1 reverse transcriptase , 2005, Peptides.

[25]  M. Zanetti.  The role of cathelicidins in the innate host defenses of mammals. , 2005, Current issues in molecular biology.

[26]  F. Yarovinsky,et al.  Mouse Cathelin-Related Antimicrobial Peptide Chemoattracts Leukocytes Using Formyl Peptide Receptor-Like 1/Mouse Formyl Peptide Receptor-Like 2 as the Receptor and Acts as an Immune Adjuvant1 , 2005, The Journal of Immunology.

[27]  M. Kagnoff,et al.  Cathelicidin Mediates Innate Intestinal Defense against Colonization with Epithelial Adherent Bacterial Pathogens1 , 2005, The Journal of Immunology.

[28]  A. Di Nardo,et al.  Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. , 2005, The Journal of investigative dermatology.

[29]  John H. White,et al.  Cutting Edge: 1,25-Dihydroxyvitamin D3 Is a Direct Inducer of Antimicrobial Peptide Gene Expression , 2004, The Journal of Immunology.

[30]  T. Ley,et al.  Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. , 2004, Blood.

[31]  Hiroshi Isogai,et al.  C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. , 2004, Cancer letters.

[32]  M. Wewers,et al.  A Novel P2X7 Receptor Activator, the Human Cathelicidin-Derived Peptide LL37, Induces IL-1β Processing and Release1 , 2004, The Journal of Immunology.

[33]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[34]  B. Finlay,et al.  Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Godowski,et al.  APC-Independent Activation of NK Cells by the Toll-Like Receptor 3 Agonist Double-Stranded RNA , 2004, The Journal of Immunology.

[36]  Niv Papo,et al.  New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. , 2003, Biochemistry.

[37]  S. Zahler,et al.  An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. , 2003, The Journal of clinical investigation.

[38]  A. Vitiello,et al.  Cutting Edge: Mast Cell Antimicrobial Activity Is Mediated by Expression of Cathelicidin Antimicrobial Peptide 1 , 2003, The Journal of Immunology.

[39]  M. Smyth,et al.  Cutting Edge: Tumor Rejection Mediated by NKG2D Receptor-Ligand Interaction Is Dependent upon Perforin1 , 2002, The Journal of Immunology.

[40]  Göran Carlsson,et al.  Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study , 2002, The Lancet.

[41]  Mark J. Smyth,et al.  Functional significance of the perforin/granzyme cell death pathway , 2002, Nature Reviews Immunology.

[42]  W. Yokoyama,et al.  In vivo developmental stages in murine natural killer cell maturation , 2002, Nature Immunology.

[43]  Takaaki Ohtake,et al.  Innate antimicrobial peptide protects the skin from invasive bacterial infection , 2001, Nature.

[44]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[45]  V. Nizet,et al.  Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. , 2001, The Journal of investigative dermatology.

[46]  J. Larrick,et al.  Interaction of CAP18-derived peptides with membranes made from endotoxins or phospholipids. , 2001, Biophysical journal.

[47]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[48]  H. Jörnvall,et al.  The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. , 2000, Blood.

[49]  Ji Ming Wang,et al.  Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells , 2000, The Journal of experimental medicine.

[50]  Eric O Long,et al.  Exposing tumor cells to killer cell attack , 2000, Nature Medicine.

[51]  I. Weissman,et al.  In vivo natural killer cell activities revealed by natural killer cell-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  C. Kozak,et al.  Identification of CRAMP, a Cathelin-related Antimicrobial Peptide Expressed in the Embryonic and Adult Mouse* , 1997, The Journal of Biological Chemistry.

[53]  R. Zinkernagel,et al.  Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.

[54]  J. Odeberg,et al.  The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. , 1996, European journal of biochemistry.

[55]  J. Schmitz,et al.  Determination of natural killer cell function by flow cytometry , 1996, Clinical and diagnostic laboratory immunology.

[56]  R. Zinkernagel,et al.  Perforin dependence of natural killer cell‐mediated tumor control in vivo , 1995, European journal of immunology.

[57]  L. Lebeck,et al.  Rapid flow cytometric assay for the assessment of natural killer cell activity. , 1993, Journal of immunological methods.

[58]  A. Gazdar,et al.  Antitumor activity of magainin analogues against human lung cancer cell lines. , 1992, Cancer research.

[59]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[60]  E. Lotzová,et al.  Interleukin-2 corrects defective NK activity of patients with leukemia. , 1986, Comparative immunology, microbiology and infectious diseases.

[61]  G. Klein,et al.  YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. , 1985, Journal of immunology.

[62]  M. Hoffmann,et al.  Modulation of interferon-induced NK cells by interleukin 2 and cAMP. , 1982, Lymphokine research.

[63]  J. Djeu,et al.  The effect of immunopharmacological agents on mouse natural cell-mediated cytotoxicity and on its augmentation by poly I:C. , 1979, Immunopharmacology.

[64]  J. Djeu,et al.  Role of macrophages in the augementation of mouse natural killer cell activity by poly I:C and interferon. , 1979, Journal of immunology.

[65]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.